Balance Sheet

Accounts Payables Accumulated Expenses Assets Capital Leases Cash & Current Investments Cash & Equivalents Common Equity Convertible Debt Curent Deferred Tax Liability Current Assets Current Deferred Revenue Current Deferred Tax Assets Current Leases Current Taxes Goodwill Goodwill & Intangibles Intangibles Inventory Liabilities and Shareholders Equity Liabilities from Discontinued Operations Long-Term Deferred Tax Long-Term Investments Minority Interest Non-Current Assets Non-Current Debt Non-Current Deferred Tax Liability Non-Current Deffered Revenue Notes Payables Operating Leases Other Accumulated Expenses Other Non-Current Assets Other Non-Current Liabilities Payables Preferred Stock Liabilities Prepaid Assets Property, Plant & Equipment (Net)Raw Materials Receivables Receivables - Net Receivables - Other Retained Earnings Shareholder's Equity Short term Debt Short-term Investments Total Current Liabilities Total Debt Total Liabilities Total Non-Current Liabilities Treasury Shares Work In Process

Growth Metrics

Others

Ligand Pharmaceuticals (LGNYZ) Total Debt (2016 - 2025)

Historic Total Debt for Ligand Pharmaceuticals (LGNYZ) over the last 12 years, with Q3 2025 value amounting to $445.5 million.

Ligand Pharmaceuticals' Total Debt changed N/A to $445.5 million in Q3 2025 from the same period last year, while for Sep 2025 it was $445.5 million, marking a year-over-year change of. This contributed to the annual value of $76.7 million for FY2022, which is N/A changed from last year.
According to the latest figures from Q3 2025, Ligand Pharmaceuticals' Total Debt is $445.5 million.
Ligand Pharmaceuticals' 5-year Total Debt high stood at $445.5 million for Q3 2025, and its period low was $76.6 million during Q3 2022.
Moreover, its 3-year median value for Total Debt was $76.8 million (2023), whereas its average is $158.1 million.